Yo, what’s good? My name’s Dan and I’m here to tell you about CaaMTech, a dope company that’s on the cutting edge of mental health research. They got a patent in 2021 for their work developing pharmaceutical drugs to treat depression and obsessive-compulsive disorder, and now they’re looking into the therapeutic value of psilocybin and cannabinoids together.
According to an article on Greenstate, CaaMTech has isolated some sick derivatives of psilocybin, cannabinoids, and terpenes. The founder and CEO, Dr. Andrew Chadeayne, said in the patent announcement that their goal has always been to capture as much of their scientific innovation as possible in their intellectual property portfolio as they develop the next generation of psychedelic drugs.
He also said that getting the patent was a huge win for the team that’s been grinding for four years to make it happen. And with hundreds more applications to prosecute, this is just the beginning.
Strong patent protection and fundamental research are key to getting their drugs through clinical trials and approved by the FDA. Their patent covers the synergistic modulatory effects of cannabinoids on serotonin receptors when administered with a serotonin agonist. Basically, CaaMTech has shown that cannabinoids work together with psychedelic tryptamines to produce some sick effects. And they’re proving that two drugs once considered to have “no known medical value” can actually treat some of the toughest mental health issues out there.
The notice of allowance from the US Patent and Trademark Office (USPTO) is a huge moment for CaaMTech’s intellectual property team, which has filed over one hundred additional patent applications since 2017. This is the final step before the patent is issued.
Since getting the patent in 2021, Greenstate reports that CaaMTech has shared findings related to 4-PrO-DMT as a dope synthetic alternative to psilocybin. And they’re not stopping there. Other research efforts like the SABI Mind survey are creating wider access for patients seeking science-based psychedelic therapies.
But developing this compound won’t be easy. MJBizDaily explains that there are serious obstacles to creating a combo compound. Cannabinoids and psychedelics act on different receptors in the brain. THC binds primarily to the CB1 cannabinoid receptor, while CBC binds primarily to the CB2 receptor. Psilocybin binds mainly to 5-HT2A serotonin receptors.
But there’s also research showing that CBD can bind to serotonin, and when serotonin is joined with a CB2 cannabinoid receptor, they can do some crazy things together. The medical cannabis community is getting hyped about the potential of this combo compound, especially after finding that cannabis combined with psychedelics can shrink tumors significantly in breast cancer.
CaaMTech is based in Issaquah, Washington and they’re all about engineering psychedelic drugs that meet modern medicine standards. So if you’re looking for some sick new treatments for mental health issues, keep an eye on CaaMTech. They’re definitely gonna be making waves in the medical world. Peace out!